Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
656 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02205047 | Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma(INNOVATION) | completed | Phase 2 | 172 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 13 | Jul 31, 2025 | clinicaltrials |
| NCT03421288 | Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness(DANTE) | active not recruiting | Phase 2 | 677 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest |
| 2 |
| Jul 25, 2025 |
| clinicaltrials |
| NCT06319794 | Study on the Safety and Efficacy of Bimiralisib Gel in Participants Suffering From Actinic Keratosis | completed | Phase 2 | 46 | TORQURINDUSTRY | 1 | Jul 18, 2025 | clinicaltrials |
| NCT02234050 | Trabectedin for Recurrent Grade II/III Meningioma | completed | Phase 2 | 90 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 10 | Jul 10, 2025 | clinicaltrials |
| NCT02611024 | Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors | completed | Phase 1 / Phase 2 | 316 | PharmaMarINDUSTRY | 6 | Jul 9, 2025 | clinicaltrials |
| NCT02637687 | A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children(SCOUT) | active not recruiting | Phase 1 / Phase 2 | 154 | BayerINDUSTRY | 21 | Jun 22, 2025 | clinicaltrials |
| NCT01197885 | Efficacy and Safety Study of Multiple Doses of IMAB362 in Patients With Advanced Gastroesophageal Cancer | completed | Phase 2 | 54 | Ganymed Pharmaceuticals GmbHINDUSTRY | 5 | Jun 13, 2025 | clinicaltrials |
| NCT03297593 | Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma | completed | Phase 2 | 74 | Swiss Cancer InstituteOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT00945724 | Safety and Feasibility Study of Combination of State of Art Chemoimmunotherapy, Intensive Central Nervous System Prophylaxis and Scrotal Irradiation to Treat Primary Diffuse Large B-cell Lymphoma of Testis(IELSG30) | completed | Phase 2 | 54 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 2 | May 30, 2025 | clinicaltrials |
| NCT06455358 | 61Cu-NODAGA-LM3 PET/CT for the Detection of Neuroendocrine Tumors (COPPER PET in NET) | recruiting | Phase 1 / Phase 2 | 27 | University Hospital, Basel, SwitzerlandOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT06138990 | Pharmacoscopy-guided Clinical Standard-of-care in r/r AML(RAPID-01) | recruiting | Phase 2 | 88 | ETH ZurichOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT03665545 | Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma(IMA950-106) | completed | Phase 1 / Phase 2 | 18 | University Hospital, GenevaOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT03406650 | Neoadjuvant and Adjuvant Durvalumab in Combination With Neoadjuvant Chemotherapy in Patients With Operable Urothelial Cancer.(SAKK 06/17) | completed | Phase 2 | 61 | Swiss Cancer InstituteOTHER | 2 | May 4, 2025 | clinicaltrials |
| NCT03110107 | First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 376 | Bristol-Myers SquibbINDUSTRY | 17 | Apr 24, 2025 | clinicaltrials |
| NCT04997317 | Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide(PROMENADE) | recruiting | Phase 1 / Phase 2 | 18 | University Hospital, Basel, SwitzerlandOTHER | 1 | Apr 13, 2025 | clinicaltrials |
| NCT04775485 | A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors(FIREFLY-1) | recruiting | Phase 2 | 141 | Day One Biopharmaceuticals, Inc.INDUSTRY | 11 | Apr 10, 2025 | clinicaltrials |
| NCT03132636 | PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy | completed | Phase 2 | 138 | Regeneron PharmaceuticalsINDUSTRY | 10 | Apr 8, 2025 | clinicaltrials |
| NCT06281106 | TYK2 Inhibition in Paradoxical Psoriasis(TYPP) | terminated | Phase 2 / Phase 3 | 2 | Prof Curdin ConradOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT03187210 | Brentuximab Vedotin and BeEAM High-dose Chemotherapy in Lymphomas(BAL) | suspended | Phase 1 / Phase 2 | 20 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT03442673 | Chemotherapy and G-CSF for Mobilization(MOCCCA) | completed | Phase 2 | 137 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT04952753 | Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC(daNIS-3) | terminated | Phase 2 | 204 | Novartis PharmaceuticalsINDUSTRY | 17 | Mar 26, 2025 | clinicaltrials |
| NCT05688241 | EBV-Tscm Cytotoxic T Cells (CTLs) for EBV- Driven Lymphomas/ Diseases(ESPECT) | not yet recruiting | Phase 1 / Phase 2 | 10 | University Hospital, Basel, SwitzerlandOTHER | 1 | Mar 3, 2025 | clinicaltrials |
| NCT04807192 | CMP-001 and Pre-operative Stereotactic Body Radiation Therapy (SBRT) in Early Stage Triple Negative Breast Cancer (TNBC) | active not recruiting | Phase 2 | 40 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT06054477 | Study of ALE.C04 in Patients With Head and Neck Cancer | terminated | Phase 1 / Phase 2 | 21 | Alentis Therapeutics AGINDUSTRY | 8 | Feb 17, 2025 | clinicaltrials |
| NCT01593241 | Therapy De-escalation in Seminoma Stage IIA/B | terminated | Phase 2 | 120 | Swiss Cancer InstituteOTHER | 2 | Feb 13, 2025 | clinicaltrials |
| NCT03150862 | A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma | completed | Phase 1 / Phase 2 | 116 | BeiGene USA, Inc.INDUSTRY | 5 | Feb 4, 2025 | clinicaltrials |
| NCT03187223 | Bendamustine and Melphalan in Myeloma(BEB-2) | completed | Phase 2 | 120 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT03495960 | Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System(FIORELLA) | completed | Phase 2 | 72 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 4 | Jan 30, 2025 | clinicaltrials |
| NCT02960230 | H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas | completed | Phase 1 / Phase 2 | 50 | Sabine Mueller, MD, PhDOTHER | 2 | Jan 22, 2025 | clinicaltrials |
| NCT05688280 | Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS(INJECTABL-1) | active not recruiting | Phase 1 / Phase 2 | 42 | Immunophotonics, Inc.INDUSTRY | 5 | Jan 8, 2025 | clinicaltrials |
| NCT03768505 | Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL) | terminated | Phase 2 | 169 | MEI Pharma, Inc.INDUSTRY | 14 | Dec 31, 2024 | clinicaltrials |
| NCT03484702 | Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma(TRANSCENDWORLD) | completed | Phase 2 | 113 | CelgeneINDUSTRY | 11 | Dec 27, 2024 | clinicaltrials |
| NCT03569241 | PEACE V: Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases(STORM) | active not recruiting | Phase 2 | 196 | University Hospital, GhentOTHER | 6 | Dec 9, 2024 | clinicaltrials |
| NCT04675827 | De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade(Decrescendo) | terminated | Phase 2 | 139 | Jules Bordet InstituteOTHER | 6 | Dec 4, 2024 | clinicaltrials |
| NCT00889382 | A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors) | completed | Phase 1 / Phase 2 | 152 | Astellas Pharma IncINDUSTRY | 10 | Nov 20, 2024 | clinicaltrials |
| NCT06068153 | AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLC(AMBER) | withdrawn | Phase 2 | 0 | ETOP IBCSG Partners FoundationNETWORK | 4 | Nov 20, 2024 | clinicaltrials |
| NCT05394350 | A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-1088-002) | terminated | Phase 1 / Phase 2 | 27 | Merck Sharp & Dohme LLCINDUSTRY | 5 | Nov 8, 2024 | clinicaltrials |
| NCT04652258 | Pyrexia Management Using an IL-6 Antibody in BRAF+ Melanoma Patients Treated with Dabrafenib/ Trametinib +/- Immunotherapy(Nov IIT- Pyrex) | terminated | Phase 2 | 20 | University of ZurichOTHER | 1 | Nov 1, 2024 | clinicaltrials |
| NCT03207867 | A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma | terminated | Phase 2 | 315 | Novartis PharmaceuticalsINDUSTRY | 15 | Oct 9, 2024 | clinicaltrials |
| NCT03177187 | Combination Study of AZD5069 and Enzalutamide.(ACE) | terminated | Phase 1 / Phase 2 | 30 | Institute of Cancer Research, United KingdomOTHER | 2 | Sep 26, 2024 | clinicaltrials |
| NCT00626106 | QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer | completed | Phase 2 | 156 | NantCell, Inc.INDUSTRY | 9 | Sep 19, 2024 | clinicaltrials |
| NCT04097470 | Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS Patients(HO155) | active not recruiting | Phase 2 | 140 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 4 | Sep 19, 2024 | clinicaltrials |
| NCT02953301 | Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS)(RESMAIN) | completed | Phase 2 | 201 | 4SC AGINDUSTRY | 12 | Aug 30, 2024 | clinicaltrials |
| NCT01970865 | A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations | completed | Phase 1 / Phase 2 | 364 | PfizerINDUSTRY | 14 | Aug 12, 2024 | clinicaltrials |
| NCT02509507 | Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611(MASTERKEY-318) | completed | Phase 1 / Phase 2 | 127 | AmgenINDUSTRY | 9 | Aug 6, 2024 | clinicaltrials |
| NCT04679480 | Anti-PD1-antibody and Pulsed HHI for Advanced BCC | unknown | Phase 2 | 20 | Reinhard DummerOTHER | 1 | Jul 30, 2024 | clinicaltrials |
| NCT03336216 | A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer | completed | Phase 2 | 205 | Bristol-Myers SquibbINDUSTRY | 11 | Jul 23, 2024 | clinicaltrials |
| NCT05013099 | Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies(iPREDICT) | unknown | Phase 2 | 70 | ImaginAb, Inc.INDUSTRY | 6 | Jul 22, 2024 | clinicaltrials |
| NCT02646098 | CD34+ Selected ASCT for Aggressive Lymphomas(SAAL) | completed | Phase 2 | 64 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Jul 8, 2024 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials